Thymosin Beta-4 (TB-4, full-length)
43-amino-acid actin-sequestering peptide
At a glance
What it is: 43-amino-acid actin-sequestering peptide.
Primary research applications:
- Ophthalmology (dry eye, corneal healing — Phase 2 evidence)
- Cardiac repair (investigational)
- Claimed: broader tissue regeneration
Editorial summary: Thymosin Beta-4 is the 'full-length parent' of TB-500 — and, unlike TB-500, it has been studied in real Phase 2 human trials, most consistently in ophthalmology. The therapeutic story for cardiac and systemic repair is still preclinical.
What is Thymosin Beta-4?
Thymosin Beta-4 is a 43-amino-acid peptide found ubiquitously in mammalian cells, where it sequesters actin monomers and participates in cell migration, tissue repair, and angiogenesis. Recombinant TB-4 (RegeneRx's RGN-259 for ophthalmology, RGN-352 for cardiac applications) has been tested in humans.[1]
Mechanism of action
Key activities:
- Sequesters actin monomers, modulating cytoskeleton
- Promotes cell migration to injury sites
- Angiogenesis
- Anti-inflammatory and anti-apoptotic effects
What the research shows
The peer-reviewed literature on Thymosin Beta-4 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Improves dry eye and corneal healing (topical) | Phase 2 RCTs | Supported |
| Promotes cardiac repair post-MI in humans | Preclinical and early human work | Preliminary |
| Is equivalent to TB-500 when administered systemically | TB-500 is a shorter fragment; equivalence not established | Uncertain |
Reported user experiences
How the research describes administration
Topical ophthalmic formulations in clinical trials; subcutaneous and intravenous routes in cardiac and systemic research.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Thymosin Beta-4 is a real, legitimate drug candidate in ophthalmology and regenerative medicine with Phase 2 human data. It is notably different from the grey-market TB-500 fragment, which borrows TB-4's reputation without matching its clinical substantiation.
Frequently asked questions
Is TB-4 the same as TB-500?
No. TB-4 is the full 43-amino-acid molecule with a real clinical development program. TB-500 is a 17-amino-acid synthetic fragment sold as a 'research chemical'.
Is TB-4 approved?
Not as of early 2026. Phase 2 and Phase 3 work has been primarily in ophthalmology (RGN-259).
Why haven't I heard of RGN-259?
Development has been slower than comparable programs. Regulatory filings for corneal indications may lead to approval in coming years, but timelines have historically slipped.
References
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a Phase 2 randomized trial. Cornea. 2015;34(5):491-6. https://pubmed.ncbi.nlm.nih.gov/25811720/